We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Alex Dav Inv. | LSE:ADI | London | Ordinary Share | GB00B28XMY25 | ORD 0.01P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.0575 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.0575 | GBX |
Alex Dav Inv. (ADI) Share Charts1 Year Alex Dav Inv. Chart |
|
1 Month Alex Dav Inv. Chart |
Intraday Alex Dav Inv. Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 20/9/2017 | 06:37 | If Carlsberg done AIM Shells - ADI 2013 | 439 |
| 31/3/2014 | 10:54 | Alexander David Investments: why? | 65 |
| 09/10/2013 | 07:10 | Alexander David Investments | 5,311 |
| 29/5/2013 | 14:05 | Shareholder Action group vs directors | 1 |
| 12/1/2012 | 19:58 | Adriana Resources - Iron Ore 100 bagger | 42 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 04/4/2014 17:37 by soul limbo people should be made aware of rampers posting on here.... lying duplicitous ramping charlatans. One of them ramped CLON to high heaven and posted reams and reams of garbage... and then dumped... look at the share price now :Currently at an all time low. |
Posted at 03/4/2014 21:48 by stockonomist The placing price is 0.004p !So this still has 50% downside. however that 0.004p valuation for this biotech Company nobody had heard of before is entirely notional (i.e. made up) What sort of proper Company would choose to RTO through the backdoor of such a p.o.s as ADI Somebody hasn't done their Due Diligence and thus I would be highly dubious about the 0.004p valuation holding up to market scrutiny once this p.o.s relists Any mug punters left in this deserve to get wiped out for being so thick |
Posted at 03/4/2014 18:15 by soul limbo same poster who is now ramping this pos, also ramped clon :Torrid share price performance. Currently at an all time low. |
Posted at 03/4/2014 08:07 by share_shark Received letter this am, dated the 31st.March with regards to Generel Meeting and circular(which comprises an Admission Doc) From ADI PLC.most can be viewed on website. Click on "investor relations" and then click onthe"shareholder Documentation " link on the website at www.ad-investments.c Will answer any further questions if I can but you will find out most of it there, I should think. I have also emailed Tim and asked questions which included ossammys question yesterday regarding RGT. If I hear back, will post here. |
Posted at 01/4/2014 22:49 by lean5gb Anyone pumping ADI is clearly not to be trusted . . .FACT ! |
Posted at 01/4/2014 21:33 by share_shark Today from Beauforts.Alexander David Investments (ADI.L, 0.10p) - Speculative Buy Alexander David Investments (ADI) released its final results for the year ended 31st December 2013. Gross portfolio return totalled £3,000 as against a negative return of -£195,000 in 2012. However, administrative expense during the year contracted to £286,000 from £458,000, resulting in total losses of £283,000 in 2013 vis-à-vis loss of £653,000 in 2012. Loss per share improved to -0.05p from -0.15p. The company provided full provision for its investment in ReGen Therapeutics (RTL), with additional £93,000 provision in 2013 on account of RTL's continuing poor sales from Colostrinin. During the year, Planwise Group invested £155,000 in equity and £200,000 through a loan into ADI, which was used by the latter to reduce its debt levels and provide for additional working capital. After negotiations with Planwise regarding the proposed reverse takeover failed to materialise, the company resumed its trading on the AIM on 30th August 2013. On 19th December 2013, Alexander entered into another agreement with Planwise for issue of £400,000 convertible loan notes for funding the costs and expenses of a possible reverse takeover. As such, the trading was suspended again with immediate effect. The same day, the company announced signing of a conditional agreement for acquisition of the entire issued share capital of Tiziana Pharma for £7.5m. If completed, the acquisition would be of sufficient size to represent a reverse takeover. The deal is subject to the approval of shareholders. ADI has already raised £2m before expenses through a placing for developing the intellectual property rights in Tiziana Pharma and for general working capital needs. If the plan is approved by the shareholders, ADI would change its name to Tiziana Life Sciences PLC. ADI announced the publication of an admission document and the resumption of the trading operations on Monday. The stock closed up 11.8%. Our view: ADI's proposed acquisition of Tiziana Pharma is likely to position it as a development stage biotechnology firm. The upcoming work programme of Tiziana Pharma includes mainly the development of drug for application in the therapeutic area of metastatic breast cancer. The lifting of trading suspension into the company's share this morning presents a lucrative opportunity to catch the upside offered through the deal. We recommend a Speculative Buy. |
Posted at 31/3/2014 07:10 by asmodeus Proposed acquisition of Tiziana Pharma LimitedPlacing of 16,666,667 New Ordinary Shares at a price of £0.12 per share Change of name to Tiziana Life Sciences PLC 300:1 share consolidation Notice of general meeting Alexander David Investments plc (AIM: ADI), announces that a circular, comprising an admission document ("Admission Document") and a notice of general meeting, has been posted to shareholders. Defined terms in this announcement have the same meaning as those in the Admission Document. To view this announcement in full, please click on the link below and see 'Latest News': |
Posted at 31/3/2014 07:06 by share_shark nder David Investments PLC Publication Of Admission Document & Lifting Of Suspension Proposed acquisition of Tiziana Pharma Limited TIDMADI 31 March 2014 Alexander David Investments plc (to be renamed Tiziana Life Sciences PLC) (the "Company") PUBLICATION OF ADMISSION DOCUMENT & LIFTING OF SUSPENSION Proposed acquisition of Tiziana Pharma Limited Placing of 16,666,667 New Ordinary Shares at a price of GBP0.12 per share Change of name to Tiziana Life Sciences PLC 300:1 share consolidation Notice of general meeting Alexander David Investments plc (AIM: ADI), announces that a circular, comprising an admission document ("Admission Document") and a notice of general meeting, has been posted to shareholders. Defined terms in this announcement have the same meaning as those in the Admission Document. A copy of the circular may be downloaded from the Company's website at www.ad-investments.c Following publication of the Admission Document, the temporary suspension to trading in the Company's shares will be lifted with effect from 7:30 a.m. today and trading in the Company's shares will resume at 8:00 a.m. Summary The Company is pleased to announce that it has conditionally agreed terms in respect of the proposed acquisition of the entire issued share capital of Tiziana Pharma, which is a development stage biotechnology company. The consideration of GBP7.50 million is to be satisfied by the issue of New Ordinary Shares at a price of GBP0.12 per share, which values the Existing Share Capital at GBP0.24 million, representing a 53 per cent. discount to the Company's share price on 19 December 2013, the date on which trading was temporarily suspended. The Company has raised GBP2.00 million (before expenses) by means of the Placing which will be used to develop the intellectual property rights in Tiziana Pharma and for general working capital purposes. The Acquisition, if completed, is of sufficient size to constitute a reverse takeover under the AIM Rules and therefore is subject to the approval of shareholders at a General Meeting. Tiziana Pharma -- Tiziana Pharma was formed in November 2013 as a vehicle to acquire and exploit certain intellectual property in biotechnology. -- Tiziana Pharma's mission is to discover and develop novel molecules that impact human disease in the area of oncology, with a particular focus on metastatic cancers. -- The first of Tiziana Pharma's programmes seeks to develop a drug for application in the therapeutic area of metastatic breast cancer. -- The intellectual property was developed by Dr Andrea Brancale (senior research academic), Dr Richard Clarkson (senior research academic) and Dr Andrew Westwell (reader in Medicinal Chemistry), all of whom are from Cardiff University. -- The intellectual property focuses on targeting the product of the B-cell Lymphoma 3 gene (Bcl-3), the inhibition of which affects a cancer cell's ability to migrate. Gabriele Cerrone, Executive Chairman of Tiziana Pharma, said: "The spread of tumors around the body, termed metastasis, accounts for approximately 90 per cent. of all cancer-related deaths. The board of Tiziana Pharma believe that there is an unmet need in the breast cancer field for increased efficacy over existing therapies, and that there is therefore a ready market for a novel treatment that is able to improve survival in patients diagnosed with cancer who might progress to metastatic disease. Tiziana Pharma's research team is attributed with the discovery that Bcl-3 has a prominent role in the metastasis of mammary cancers. Furthermore, Tiziana Pharma's lead compound has shown significant anti-metastatic activity in preclinical trials designed to demonstrate the inhibition of disease progression and further spread of metastatic lesions. Aided by the enlarged group's strengthened balance sheet and access to public markets via an AIM listing, we look forward to building on our success to date by progressing this promising candidate into phase I clinical trials, and creating shareholder value growth in the medium and longer term." Enquiries |
Posted at 19/10/2013 10:12 by harrysbank For any newer holders curious to understand more on ADI Regen Ltd relationship."Technically this loan [£270k] can be called upon after 14th February 2014, although at the election of either Alexander David Investments Plc ("ADI") or the Company it can be converted into Regen Therapeutics Limited Shares". We anticipate Regen provides a c£20m IP and tax loss value (In Regen Finance statement 2011 "tax trading loses' were 'approx £14.2m' (page 15) Brands from Regen Colostrinin include Zolpidem - this is one of many where no further work will be undertaken unless finances turn up for Regen However, Dr Clauss continues to work with the product where NHS patients seek him out and results contine to provide encouragement Example of his twitter updates ( Survivors of severe brain injuries may end up in a state of 'wakeful unresponsiveness' or in a minimally conscious state. Pharmacological treatments of patients with disorders of consciousness aim to improve arousal levels and recovery of consciousness. We here provide a systematic overview of the therapeutic effects of amantadine, apomorphine and zolpidem in patients recovering from coma. |
Posted at 27/9/2013 09:55 by greedfear Well it's all very clear now, isn't it?1. Planwise is factually in full and total control over ADI; 2. PJ realised he would be fighting a lost battle and jumped ship; 3. ADI must draw down on the 200,000 Planwise loan facility to pay for admnistrative expenses (115,000 for last half year); 4. Loan from Planwise must be repaid in cash, but ADI can't 5. Because ADI can't repay in cash, Planwise could: a. demand repayment by handing over all the ADI assets (RTL shares + RTL convertible loan, so very conveniently written off to 72,000 [maybe even written off more in not to distant future] to Planwise and/or b)convert (what's left of) the loan into equity, without a doubt at the lowest price possible (0.01p?), diluting current ADI shareholders like crazy. 6. Market the shell (leaving current holders with next to nothing). Offcourse only my opinion, but I think this scenario, in which current holders will be left with almost nothing becomes reality soon. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
